Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anatara Lifesciences Ltd ( (AU:ANR) ) has shared an update.
Anatara Lifesciences Ltd reported a 35% increase in net loss after tax for the year ending June 30, 2025, amounting to $1,954,702. Despite the financial setback, the company’s operations and activities continue without changes in controlled entities, and the financial statements received an unqualified audit opinion, albeit with an emphasis on going concern.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd operates in the biotechnology industry, focusing on developing and commercializing products for gastrointestinal health. The company targets both human and animal health markets, aiming to address unmet medical needs with innovative solutions.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$1.92M
For a thorough assessment of ANR stock, go to TipRanks’ Stock Analysis page.